Participants in the BioBusiness Summer School get the opportunity to learn more about specific positions and organisations within the industry during 30 or 45-minute Meet your Match sessions. We have selected the following professionals for this years' Meet your Match:
Wim has served as CSO of Byondis since 2019. Wim is a seasoned scientist, having operated within the pharma and biotech industries for over 20 years. He has a proven track record of leading drug development programs with large international and multidisciplinary teams to successfully reach key milestones, including delivery of several clinical drug candidates in oncology, autoimmunity and diabetes. Preceding his appointment to CSO, Wim was Executive Vice President Preclinical at Synthon Biopharmaceuticals. Prior this, he was Director of Pharmacology and Immunology Program Leader at Schering-Plough, which ultimately merged with Merck & Co. (MSD). Before this, he built his career in R&D through a progression of roles at Organon.Wim’s scientific expertise is exemplified by the 50+ peer-reviewed publications in scientific journals that he has co-authored. Wim holds an MSc in (Bio)Chemistry and a PhD in Hematology and Oncology, both from the University of Groningen, the Netherlands.
About Byondis
Driven to improve patients’ lives, Byondis is an independent, privately held, clinical stage biopharmaceutical company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. The company is developing new biological entities (NBEs) and new chemical entities (NCEs) using proprietary molecular concepts, such as ByonZine®, its duocarmazine linker-drug (LD) technology and ByonShieLD®, its site-specific conjugation technology, to generate next generation antibody-drug conjugates (ADCs).
Byondis’ broad portfolio comprises preclinical as well as early- and late-stage clinical development programs, including the anti-HER2 ADC [vic-]trastuzumab duocarmazine (SYD985, Phase III). The company has a dedicated team of around 400 staff, including highly educated scientists and skilled technicians working in state-of-the-art Research and Development laboratories and Good Manufacturing Practice manufacturing facilities at its Nijmegen campus in the Netherlands. Byondis regularly collaborates with globally renowned biotechnology and pharmaceutical companies and academic research institutions.
Gemma Moiset obtained her PhD in Life Sciences from the University of Groningen in the lab of Prof. Dr. Bert Poolman. Immediately after, she joined the Netherlands Cancer Institute (NKI) as a postdoc with Prof. Dr. Huib Ovaa where she worked on the design and screening of inhibitors for oncotargets. Two years after, she joined the biotech AIMM Therapeutics as a Scientist for five years, where she contributed to the discovery and development of novel monoclonal antibodies from cured cancer patients. Recently, she has joined the contract research organization Charles River Laboratories as Group Leader.
About Charles River Laboratories
Charles River is an early-stage CRO with a diverse portfolio of discovery and safety assessment services to support clients from target identification through preclinical development. We also provide products and services to support clinical laboratory testing needs and manufacturing activities. We are passionate about our role in improving the quality of people’s lives and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. Charles River is an early-stage CRO with a diverse portfolio of discovery and safety assessment services to support clients from target identification through preclinical development. We also provide products and services to support clinical laboratory testing needs and manufacturing activities. We are passionate about our role in improving the quality of people’s lives and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.
Ernst has over 10 years of experience in cancer research, oncology drug development and venturing. Ernst holds a PhD in molecular cancer genetics from the Netherlands Cancer Institute (NKI-AvL) after which he continued his career as business developer at the research- and technology organization TNO, where he had a role in spinning-of biotech companies. As partner at Aglaia he is responsible for analysis of investment proposals, scouting of new investment opportunities and offers strategic and operational support to Aglaia’s portfolio companies. He was managing director for Sapreme Technologies and is currently a board observer for Macrophage Pharma and Sapreme Technologies.
About Aglaia
Aglaia Oncology Funds is an investment firm which fully specializes in and focusses on investing in oncology ventures. Aglaia has been in operation since 2004. The team has decades of experience in cancer research and oncology drug development, having been involved in the development of more than 100 oncology products. Aglaia has invested in 13 early stage companies, of which 6 were founded by Aglaia. Aglaia’s vision is that when stellar science is translated into great medicines for cancer patients, financial rewards for those involved in this process will ultimately follow. The continuous strategic and operational involvement of the team with portfolio companies has contributed to a marked success rate in transitioning early-stage portfolio companies to clinical-stage companies. By doing so, Aglaia has de-risked and matured these companies up to the level at which they became attractive candidates for licensing, acquisition or IPO. Examples are Merus, which became listed on the NASDAQ and Syntarga, which was sold to Synthon. More importantly, 800 cancer patients have been treated so far with investigational drugs developed by Aglaia’s portfolio companies.
About GenDx
GenDx supports diagnostic laboratories with the newest technologies for high resolution HLA typing by Next Generation Sequencing strategies and Chimerism monitoring, tailored to enhance the outcome of transplantation. In GenDx we believe that progress can be best achieved through partnerships but also by keeping our independent position and a strong focus on education of the end-users. The close-knit management team aims to create a working atmosphere with ample room for personal development, job satisfaction and a transparent way of communication. At the moment GenDx has about 60 employees.
Powered by: BCF Courses BV | Connect with us | Join BioBusiness Summer School | |||
Privacy Policy Terms & Conditions Chamber of Commerce: 75874415 | | KEEP ME INFORMED |
© Copyright 2025 by BCF Courses